Dioxoles are organic compounds containing a five-membered ring consisting of two oxygen atoms and two carbon atoms, often found as substructures in various natural and synthetic molecules, including certain pharmaceuticals and toxic dioxin pollutants.

Endothelin receptor expression and pharmacology in human saphenous vein graft. (1/632)

1. We have investigated the expression and pharmacology of endothelin (ET) receptors in human aortocoronary saphenous vein grafts. 2. Subtype-selective ligands were used to autoradiographically identify ET(A) ([125I]-PD151242) and ET(B)([125I]-BQ3020) receptors. In graft saphenous vein ETA receptors predominated in the media, with few ET(B) receptors identified. Neither subtype was detected in the thickened neointima. 3. The ratio of medial ET(A):ET(B) receptors was 75%: 25% in both graft and control saphenous vein. 4. ET-1 contracted control (EC50 2.9 nM) and graft (EC50 4.5 nM) saphenous vein more potently than diseased coronary artery (EC50 25.5 nM). 5. In all three blood vessels ET-1 was 100 times more potent than ET-3 and three times more potent than sarafotoxin 6b (S6b). Little or no response was obtained in any vessel with the ET(B) agonist sarafotoxin 6c (S6c). 6. The ET(A) antagonist PD156707 (100 nM) blocked ET-1 responses in all three vessels with pKb values of approximately 8.0. 7. For individual graft veins the EC50 value for ET-1 and 'age' of graft in years showed a significant negative correlation. 8. In conclusion there is no alteration in ET receptor expression in the media of saphenous veins grafted into the coronary circulation compared to control veins. ETA receptors predominantly mediate the vasoconstrictor response to ET-1 in graft vein, with no apparent up-regulation of ET(B) receptors. The sensitivity of the graft vein to ET-1 increased with graft 'age', suggesting that these vessels may be particularly vulnerable to the increased plasma ET levels that are detected in patients with cardiovascular disease.  (+info)

Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation. (2/632)

1. The effects of intravenous administration of endothelin (ET) receptor antagonists SB-209670 (0.001-10.0 mg kg(-1)), SB-217242, SB-234551 (0.01-10.0 mg kg(-1)) and BQ-788 (0.001-1.0 mg kg(-1)) were investigated on trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the carotid vasculature of the anaesthetized cat. Comparisons were made with sumatriptan (0.003-3.0 mg kg(-1)) and alpha-CGRP8-37 (0.001-0.1 mg kg(-1)). 2. Trigeminal nerve ganglion stimulation produced frequency related increases in carotid blood flow, reductions in carotid vascular resistance and non-frequency related increases in blood pressure. Guanethidine (3 mg kg(-1), i.v.) blocked trigeminal nerve ganglion-induced increases in blood pressure but had no effect on changes in carotid flow or resistance. Maximal reductions in carotid vascular resistance was observed at 10 Hz, and this frequency was selected to investigate the effects of drugs on trigeminal nerve ganglion stimulation-induced responses in guanethidine treated cats. 3. Saline, alpha-CGRP8-37 SB-209670 and BQ-788 had little or no effect on resting haemodynamic parameters. SB-217242 (10 mg kg(-1), n=3) produced a 56% reduction in arterial blood pressure whereas SB-233451 (10 mg kg(-1), n=3) produced a 30% reduction in carotid vascular resistance. Sumatriptan produced dose-related reductions in resting carotid flow and increases (max. 104% at 0.3 mg kg(-1), n = 5) in vascular resistance. 4. SB-209670 (n=6-7), SB-217242 (n=3) and BQ-788 (n=3) produced inhibition of trigeminal nerve ganglion stimulation-induced reductions in carotid vascular resistance. Saline, SB-234551, alpha-CGRP8-37 and sumatriptan had no effect. 5. These data demonstrate ET(B) receptor blockade attenuates the vasodilator effects of trigeminal nerve ganglion stimulation in the carotid vascular bed of guanethidine pretreated anaesthetized cats.  (+info)

Synergistic interactions between ampakines and antipsychotic drugs. (3/632)

Tests were made for interactions between antipsychotic drugs and compounds that enhance synaptic currents mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptors ("ampakines"). Typical and atypical antipsychotic drugs decreased methamphetamine-induced hyperactivity in rats; the effects of near or even subthreshold doses of the antipsychotics were greatly enhanced by the ampakines. Interactions between the ampakine CX516 and low doses of different antipsychotics were generally additive and often synergistic. The ampakine did not exacerbate neuroleptic-induced catalepsy, indicating that the interaction between the different pharmacological classes was selective. These results suggest that positive modulators of cortical glutamatergic systems may be useful adjuncts in treating schizophrenia.  (+info)

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. (4/632)

A series of totally synthetic molecules that are structurally related to the marine natural product ecteinascidin 743 (Et 743) has been prepared and evaluated as antitumor agents. The most active of these, phthalascidin, is very similar to Et 743 with regard to in vitro potency and mode of action across a variety of cell types. The antiproliferative activity of phthalascidin (IC50 = 0.1-1 nM) is greater than that of the agents Taxol, camptothecin, adriamycin, mitomycin C, cisplatin, bleomycin, and etoposide by 1-3 orders of magnitude, and the mechanism of action is clearly different from these currently used drugs. Phthalascidin and Et 743 induce DNA-protein cross-linking and, although they seem to interact with topoisomerase (topo) I (but not topo II), topo I may not be the primary protein target of these agents. Phthalascidin and Et 743 show undiminished potency in camptothecin- and etoposide-resistant cells. Phthalascidin is more readily synthesized and more stable than Et 743, which is currently undergoing clinical trials. The relationship of chemical structure and antitumor activity for this class of molecules has been clarified by this study.  (+info)

Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. (5/632)

The possible existence of a beta3-adrenergic receptor (beta3-AR) in the human detrusor muscle was investigated by in vitro functional studies and analysis of mRNA expression. Isoprenaline, noradrenaline and adrenaline each produced a concentration-dependent relaxation of the human detrusor. The rank order for their relaxing potencies was isoprenaline (pD2 6.37+/-0.07) > or = noradrenaline (pD2 6.07+/-0.12) > or = adrenaline (pD2 5.88< or =0.11). Neither dobutamine (beta1- and beta2-AR agonist) nor procaterol (beta2-AR agonist) produced any significant relaxation at concentrations up to 10(-5) M. BRL37344A, CL316243 and CGP-12177A (beta3-AR agonists), relaxed the preparations significantly at concentrations higher than 10(-6) M. The pD2 values for BRL37344A, CL316243 and CGP-12177A were 6.42+/-0.25, 5.53+/-0.09 and 5.74+/-0.14, respectively. CGP-20712A (10(-7) - 10(-5) M), a beta1-AR antagonist, did not affect the isoprenaline-induced relaxation. On the other hand, ICI-118,551, a beta2-AR antagonist, produced a rightward parallel shift of the concentration-relaxation curve for isoprenaline only at the highest concentration used (10(-5) > M) and its pKB value was 5.71+/-0.19. Moreover, SR58894A (10(-7) - 10(-5) M), a beta3-AR antagonist, caused a rightward shift of the concentration-relaxation curve for isoprenaline in a concentration-dependent manner. The pA2 value and slope obtained from Schild plots were 6.24+/-0.20 and 0.68+/-0.31. The beta1-, beta2- and beta3-AR mRNAs were all positively expressed in detrusor smooth muscle preparations in a reverse transcription polymerase chain reaction assay. In conclusion, the present results provide the first evidence for the existence of the beta3-AR subtype in the human detrusor. They also suggest that the relaxation induced by adrenergic stimulation of the human detrusor is mediated mainly through beta3-AR activation.  (+info)

Aryl propanolamines: comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia. (6/632)

1. The in vitro activity of four aryl propanolamines was compared to two prototypic beta3 receptor agonists, CGP 12177 and CL316243 at the human beta3 receptor, the rat beta3 receptor in the stomach fundus and receptors mediating atrial tachycardia. 2. L-739,574 was the most potent (EC50 = 9 nM) and selective agonist at the human beta3 receptor with high maximal response (74% of the maximal response to isoproterenol). 3. A phenol-biaryl ether analogue possessed modest affinity for the human beta3 receptor (EC50 = 246 nM), but was highly efficacious with a maximal response 82% of the maximal response to isoproterenol. The other derivatives were intermediate in potency with low maximal responses. 4. These agonists at the human beta3 receptor did not activate the rat beta3 receptor in the rat stomach fundus. In fact, the aryl propanolamines (10(-6) M) inhibited CL316243-induced activation of the rat beta3 receptor. Thus, agonist activity at the human beta3 receptor translated into antagonist activity at the rat beta3 receptor. 5. L739,574 and the phenol biaryl ether increased heart rate via beta1 receptors. 6. Although CGP12177 produced atrial tachycardia, neither the indole sulphonamide nor biphenyl biaryl ether did, although both had high affinity for the human beta3 receptor. Thus, the atrial tachycardic receptor was not identical to the human beta3 receptor. 7. These studies (a) characterized four aryl propanolamines with high affinity at the human beta3 receptor, (b) found that they were antagonists at the rat beta3 receptor, an observation with profound implications for in vivo rat data, and (c) established that the rodent atrial non-beta1, beta2 or beta3 tachycardic receptor was also unrelated to the human beta3 receptor.  (+info)

The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism. (7/632)

Promiscuous coupling between G protein-coupled receptors and multiple species of heterotrimeric G proteins provides a potential mechanism for expanding the diversity of G protein-coupled receptor signaling. We have examined the mechanism and functional consequences of dual Gs/Gi protein coupling of the beta3-adrenergic receptor (beta3AR) in 3T3-F442A adipocytes. The beta3AR selective agonist disodium (R, R)-5-[2[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]propyl]-1, 3-benzodioxole-2,2-dicarboxylate (CL316,243) stimulated a dose-dependent increase in cAMP production in adipocyte plasma membrane preparations, and pretreatment of cells with pertussis toxin resulted in a further 2-fold increase in cAMP production by CL316,243. CL316,243 (5 microM) stimulated the incorporation of 8-azido-[32P]GTP into Galphas (1.57 +/- 0.12; n = 3) and Galphai (1. 68 +/- 0.13; n = 4) in adipocyte plasma membranes, directly demonstrating that beta3AR stimulation results in Gi-GTP exchange. The beta3AR-stimulated increase in 8-azido-[32P]GTP labeling of Galphai was equivalent to that obtained with the A1-adenosine receptor agonist N6-cyclopentyladenosine (1.56 +/- 0.07; n = 4), whereas inclusion of unlabeled GTP (100 microM) eliminated all binding. Stimulation of the beta3AR in 3T3-F442A adipocytes led to a 2-3-fold activation of mitogen-activated protein (MAP) kinase, as measured by extracellular signal-regulated kinase-1 and -2 (ERK1/2) phosphorylation. Pretreatment of cells with pertussis toxin (PTX) eliminated MAP kinase activation by beta3AR, demonstrating that this response required receptor coupling to Gi. Expression of the human beta3AR in HEK-293 cells reconstituted the PTX-sensitive stimulation of MAP kinase, demonstrating that this phenomenon is not exclusive to adipocytes or to the rodent beta3AR. ERK1/2 activation by the beta3AR was insensitive to the cAMP-dependent protein kinase inhibitor H-89 but was abolished by genistein and AG1478. These data indicate that constitutive beta3AR coupling to Gi proteins serves both to restrain Gs-mediated activation of adenylyl cyclase and to initiate additional signal transduction pathways, including the ERK1/2 MAP kinase cascade.  (+info)

Coronary arteriopathy in monkeys following administration of CI-1020, an endothelin A receptor antagonist. (8/632)

A selective non-peptide endothelin A (ETA) receptor antagonist, CI-1020, was administered to cynomolgus monkeys intravenously (i.v.) for 2 or 4 wk and orally for 4 wk. Groups consisting of 3 animals of each sex received CI-1020 at 1, 5, and 10 mg/kg/hr (i.v.) or orally at 250, 500, and 750 mg/kg body weight for 4 wk. Control animals received the vehicle only. In a separate experiment, 1 male was infused with 10 mg/kg/hr for 2 wk, and Monastral blue dye was administered i.v. to facilitate localization of lesions to the vascular walls. One female was administered saline and the dye and served as a control. One female at 1 mg/kg/hr was found dead at week 2, and 1 female at 5 mg/kg/hr was euthanatized during week 4 as a result of severe thigh swelling at the catheter site. Macroscopically, extramural coronary arteries appeared thickened and nodular in the 4-wk i.v. study in the female found dead at 1 mg/kg/hr, in 1 male and 1 female at 5 mg/kg/hr, and in 2 females at 10 mg/kg/hr. Histologically, Monastral blue pigment trapped in the walls of coronary arteries with arteriopathy was observed in the male treated with CI-1020 at 10 mg/kg/hr for 2 wk. Extramural coronary arteriopathy occurred at all doses in the 4-wk i.v. study, with higher incidence occurring in females than in males (7 of 9 treated females compared with 3 of 9 treated males). In the oral study, 1 female at 500 mg/kg/day and 1 male and 2 females at 750 mg/kg/day had coronary arteriopathy. Histological changes after 2 wk of treatment were characterized by intimal thickening, fragmentation of the internal elastic lamina, necrosis and edema of the media, and mixed inflammatory-cell infiltrates in the intima, media, and adventitia. After 4 wk of i.v. administration, arteriopathy was characterized by segmental disruption of the elastic lamina and intimal and medial fibrosis with complete replacement of smooth muscle with fibrous tissue. The adventitia was thickened as a result of fibrosis and mixed or mononuclear inflammatory-cell infiltrates. CI-1020 concentrations were higher in males (1.57 to 29 micrograms/ml) than in females (0.974 to 24.4 micrograms/ml) in the i.v. study. Transient systemic exposure with high maximum plasma concentration (Cmax) (120-352 micrograms/ml) in the oral study was insufficient to provoke arterial changes of the same magnitude as those noted with continuous i.v. administration. The regeneration of the media by fibrous tissue and the disruption of the elastic lamina may weaken the arterial wall and increase the susceptibility of the artery to the development of aneurysm.  (+info)

I apologize for any confusion, but "dioxoles" is not a medical term or concept. It is a chemical term that refers to a specific type of organic compound containing a dioxole ring, which is a six-membered ring consisting of two oxygen atoms and two carbon atoms. Dioxoles can be found in various natural and synthetic substances, but they are not typically relevant to medical definitions or concepts.

If you have any questions related to medical terminology or concepts, I would be happy to help answer them for you.

Nichols DE, Oberlender R, Burris K, Hoffman AJ, Johnson MP (November 1989). "Studies of dioxole ring substituted 3,4- ... 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring". Journal of Medicinal Chemistry. 22 (10): 1264-7. doi: ...
3-dioxole-co-tetrafluoroethylene) and Fumed Silica," Macromolecules. Jones, A.A.; Stockmayer, W.H. "Models for spin relaxation ...
3-dioxole used as membrane materials Teflon FEP, fluorinated ethylene propylene used as a high-temperature insulation for wire ...
... Notes. *This display requires that Java be installed on your system and your browser to ...
We also provide custom synthesis and GMP manufacturing services.where to buy Dioxoles ... where to buy Dioxoles, Chemenu is research-based manufacturer of pharmaceutical intermediates and fine chemicals offering Animo ... Cyclopentanes Dioxolanes Dioxoles Furans Furazans Imidazoles Imidazolidines Imidazolines Isothiazoles Isothiazolidines ...
Nichols DE, Oberlender R, Burris K, Hoffman AJ, Johnson MP (November 1989). "Studies of dioxole ring substituted 3,4- ... 3,4-(Methylenedioxy)amphetamine analogues alkylated on the dioxole ring". Journal of Medicinal Chemistry. 22 (10): 1264-7. doi: ...
Dioxoles--pharmacology. Isoquinolines--pharmacology. Publication Types: Webcast Rights: This is a work of the United States ...
MeSH Terms: 7-Alkoxycoumarin O-Dealkylase; Animals; Cytochrome P-450 Enzyme System/metabolism*; Dioxoles/pharmacology*; Enzyme ...
Dioxoles / pharmacology Actions. * Search in PubMed * Search in MeSH * Add to Search ...
Dioxoles / administration & dosage* Actions. * Search in PubMed * Search in MeSH * Add to Search ...
6-Nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid. Last updated: 4 December 2002 See Also: Toxicological Abbreviations ... 8-Methoxy-6-nitrophenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid *3,4-Methylenedioxy-8-methoxy-10-nitro-1- ...
2-methoxydodecahydrocyclododeca[d][1,3]dioxole *Molecular Formula: C14H26O3 ...
Dioxoles,N0000007693, Benzoic Acids,N0000007692, Propylamines,N0000007691, Amidohydrolases,N0000007690, Propoxyphene, ...
The cytochrome P450-mediated oxidative demethylenation of the benzo-1,3-dioxoles (methylenedioxyphenyl compounds, MDPs), ...
... or with a dioxole ring; and pharmaceutically acceptable salts and/or esters thereof; and. R5 is H; (C1-C5)alkyl; (C1-C6) ... or with a dioxole ring; and pharmaceutically acceptable salts and/or esters thereof; and ... or with a dioxole ring; and pharmaceutically acceptable salts and/or esters thereof; and ...
Dioxoles Tree number(s):. D03.383.246. RDF Unique Identifier:. https://id.nlm.nih.gov/mesh/D004149 ...
Dioxoles Preferred Concept UI. M0006500. Registry Number. 0. Terms. Dioxoles Preferred Term Term UI T012614. Date01/01/1999. ... Dioxoles. Tree Number(s). D03.383.246. Unique ID. D004149. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D004149 Registry ...
Dioxoles Preferred Concept UI. M0006500. Registry Number. 0. Terms. Dioxoles Preferred Term Term UI T012614. Date01/01/1999. ... Dioxoles. Tree Number(s). D03.383.246. Unique ID. D004149. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/D004149 Registry ...
Dioxole (substance) {427737006 , SNOMED-CT } Parent/Child (Relationship Type) Dioxolane (substance) {428147002 , SNOMED-CT } ...
5-nitrobenzo[d][1,3]dioxole. Products Type. Fine Chemical. Sales. Up to 100 gm. ...
DrugHypertensionDioxolesRats, Inbred WKYDansyl CompoundsCells, CulturedVasodilator AgentsPulmonary ArteryMuscle Contraction ... MessengerDioxolesDansyl CompoundsVasodilator AgentsPyrimidinesAtrial Natriuretic FactorAngiotensin IIIndolesNicardipine ...
It was observed that the carbonyl ylides from these Z-enones yielded dioxoles by electrocyclisation onto the carbonyl carbon. ...
5.6.1. 1,3-Dioxoles and Dioxolanes. *5.6.2. 1,3-Dithioles and Dithiolanes ...
Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and ...
Benzo[d][1,3]dioxole-4-carbaldehyde. CAT #: B01658. CAS #: 7797-83-3. M.F : C8H6O3. M.W : 150.13 ...
Perfluoro(2,2-dimethyl-1,3-dioxole). CAS: 37697-64-6. Catalog Number: 0777 ...
These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered ...
Dioxoles [Chemical Structural Class] Furans [Chemical Structural Class] Hydantoins [Chemical Structural Class] Imidazoles [ ...
3-dioxole fragment adopts an envelope conformation with the methyl-ene C atom forming the flap; this atom deviates by 0.232â (3 ...
... dioxole-6-carbohydrazide (B). Several methods were used to evaluate the effectiveness of Schiff bases as photo stabilizers on ... dioxole-6carbonyl chloride, and then it was reacted with hydrazine to produce 7-chlorothieno[2,3:4,5]benzo[1,2-d][1,3] ... dioxole-6carbonyl chloride, and then it was reacted with hydrazine to produce 7-chlorothieno[2,3:4,5]benzo[1,2-d][1,3]dioxole ... dioxole-6-carbonyl chloride, and then reacted with hydrazine to produce 7-chlorothieno[2,3:4,5]benzo[1,2d] [1,3]dioxole-6- ...
... dioxole-4-carbonitrile. IUPAC names 1 Other identifiers 1 ...

No FAQ available that match "dioxoles"